Article in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 10 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors at 3 institutions in 2 countries.
Obaid HayatDepartment of Biotechnology, Faculty of Chemical and Life Sciences, Abdul Wali Khan University, Mardan 23200, Pakistan.ORCID 0000-0003-4335-3300
Nazif UllahDepartment of Biotechnology, Faculty of Chemical and Life Sciences, Abdul Wali Khan University, Mardan 23200, Pakistan.ORCID 0000-0002-4564-5799
Muhammad SirajuddinDepartment of Chemistry, University of Science and Technology, Bannu 28100, Pakistan.ORCID 0000-0002-1147-1284
Miriam A GiardiniCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0002-6510-2409
Jennifer V NguyenCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0003-0194-9157
Karol R FranciscoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Lawrence J LiuCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Yujie Uli SunCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Svetlana MauryaDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA.
Dominic McGrossoDepartment of Pharmacology, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-6623-6268
David J GonzalezCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Conor R CaffreyCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.
Anjan DebnathCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9294-3927
Jair L Siqueira-NetoCenter for Discovery and Innovation in Parasitic Diseases, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, CA 92093, USA.ORCID 0000-0001-9574-8174
University of California San Diego · USAbdul Wali Khan University Mardan · PKUniversity of Science and Technology Bannu · PK
Funding
Targeting the Genus Leishmania with Small MoleculesR01AI151639 · NIAID · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI BROWN, LAUREN ELAINE, SCHAUS, SCOTT EDWARD · 2021 to 2025
$3.8M
Development of thiophen-2-yl-phenylpyrimidines for treatment of schistosomiasisR21AI156554 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BALLATORE, CARLO, CAFFREY, CONOR · 2021 to 2022
$435k
HMG-CoA Reductase Inhibitors as New Drug Leads for Naegleria InfectionR21AI146460 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEBNATH, ANJAN · 2020 to 2021
Metals have been used in medicine since ancient times for the treatment of different ailments with various elements such as iron, gold and arsenic. Metal complexes have also been reported to show antibiotic and antiparasitic activity. In this context, we tested the antiparasitic potential of 10 organotin (IV) derivatives from 4-(4-methoxyphenylamino)-4 oxobutanoic acid (MS26) against seven eukaryotic pathogens of medical importance:
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
A Broad Spectrum Antiparasitic Activity of Organotin (IV) Derivatives and Its Untargeted Proteomic Profiling Using · full record | OpenQuestion